The citrate-free high-concentration formulation injection has been approved to treat a myriad of arthritis conditions as well as ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
“The FDA approval of Hyrimoz HCF builds on the already approved and well-established Sandoz global biosimilar portfolio in immunology,” the news release states. “When it launches, Hyrimoz HCF will represent the first launch of a Sandoz biosimilar in the U.S. market in this specific disease space.”
Hyrimoz HCF met all objectives and showed similar safety levels, pharmacokinetics and immunogenicity as the already FDA-approved adalimumab 50 mg/mL to which it was compared.
As a result of the FDA’s approval, Sandoz plans to launch Hyrimoz for availability in the U.S. beginning July 1.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
